Welcome to our dedicated page for BAXTER INTERNATIONAL SEC filings (Ticker: BAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BAXTER INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BAXTER INTERNATIONAL's regulatory disclosures and financial reporting.
Ampofo William A. II reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director William A. Ampofo II received a stock grant of 12,836 shares of common stock. The shares were granted at no cash cost to him as a fully vested award, increasing his directly held stake to 30,375 shares, including shares from automatic dividend reinvestment.
This Form 4 reflects a compensation-related grant, not an open-market purchase or sale, and does not indicate any change in his trading views on Baxter stock.
Baxter International Inc. — Amendment to Schedule 13G reporting institutional ownership.
FMR LLC (with Abigail P. Johnson disclosed) reports 46,264,804.28 shares of Common Stock, representing 9.0% of the class as of 03/31/2026. The filing shows sole dispositive power for 46,264,804.28 shares and sole voting power of 32,385,962.16 shares. The amendment is signed 05/05/2026 and references an attached Exhibit 99 and a power of attorney.
Baxter International Inc. reported first-quarter 2026 net sales of $2.70 billion, up 3% from $2.63 billion a year earlier, but swung to a net loss of $15 million, or $(0.03) per diluted share, versus net income of $126 million, or $0.25 per share.
Continuing operations posted a loss of $17 million, compared with $64 million of income in 2025, despite higher gross margin dollars. Results were heavily affected by $205 million of special items, including $146 million of intangible amortization and $68 million of restructuring and business optimization charges tied largely to the Kidney Care divestiture.
By segment, Medical Products & Therapies sales rose 2%, Healthcare Systems & Technologies were flat, and Pharmaceuticals grew 7%, driven by strong international drug compounding. However, Novum IQ pump shipment holds, injectables supply constraints, inflationary cost pressures and recall- and hurricane-related items weighed on profitability.
Operating cash flow improved sharply to $213 million from a $99 million use of cash a year ago, helped by working capital improvements. Baxter ended the quarter with $2.02 billion in cash and cash equivalents and $8.62 billion of long-term debt, while continuing multiyear cost-reduction and business transformation programs.
Baxter International reported first-quarter 2026 sales from continuing operations of $2.7 billion, up 3% on a reported basis but down 1% organically, reflecting flat to modestly weaker underlying demand. U.S. sales fell 4% while international sales grew 12% reported and 3% organically.
The company posted a U.S. GAAP net loss from continuing operations of $17 million, or ($0.03) per diluted share, compared with a profit a year ago. Adjusted diluted EPS from continuing operations was $0.36, down 35% from $0.55, as higher tariffs, manufacturing costs and prior-year comparison pressures weighed on results. Baxter’s board declared a quarterly dividend of $0.01 per share and the company reiterated its full-year 2026 outlook, targeting flat to 1% reported sales growth and adjusted diluted EPS of $1.85 to $2.05.
Baxter International Inc reports that Vanguard Capital Management beneficially owns 38,033,907 shares of Common Stock. The filing states this equals 7.36% of the class and that Vanguard has sole dispositive power over 38,033,907 shares and sole voting power over 4,526,932 shares. The filing is a Schedule 13G disclosure of passive ownership.
BAXTER INTERNATIONAL INC Schedule 13G/A shows BlackRock, Inc. reports beneficial ownership of 33,109,852 shares of common stock, representing 6.4% of the class as of the cover date. The filing lists sole voting power of 31,357,784 shares and sole dispositive power of 33,109,852 shares. The amendment is signed by a BlackRock managing director on 04/27/2026.
Baxter International: Pzena Investment Management reported beneficial ownership of 65,347,621 shares of Common Stock, representing 12.7% as of 03/31/2026. The filing states Pzena has sole voting power for 53,110,244 shares and sole dispositive power for 65,347,621 shares. It notes the shares are held for clients who retain the right to dividends and sale proceeds and that no single client accounts for more than 5% of the class.
Baxter International executive Julie Foster, President of Front Line Care, filed an initial ownership report showing both stock and option holdings. She directly holds 31,248 shares of common stock and a stock option covering 25,862 shares at an exercise price of $20.37 per share, expiring on February 27, 2036. The options become exercisable in three equal annual installments beginning on March 1, 2027, the first anniversary of the grant date.
Baxter International executive Steven P. Wallace, President of Advanced Surgery, reported his initial holdings on a Form 3. He directly owns 70,282 shares of common stock and holds several stock option awards covering additional shares at exercise prices between $20.37 and $74.47 with expirations from 2032 through 2036.
Baxter International Inc. executive James Teaff filed an initial Form 3 reporting his ownership of company securities. He reports direct ownership of 31,120 shares of Baxter common stock. The filing also lists several stock option awards, each giving the right to buy Baxter common shares at set exercise prices before future expiration dates.
These options cover blocks of shares at exercise prices ranging from $20.37 to $85.23 per share, with expiration dates between 2027 and 2036. Footnotes explain that the options generally become exercisable in three equal annual installments starting on the first anniversary of their respective grant dates. The filing records current holdings and does not reflect new open-market purchases or sales.